Abstract:The general paucity of effective and specific antiviral agents, in spite of considerable effort expended by many competent research groups,’ has in part been due to the lack of adequate test systems for detecting antiviral activity apart from cytotoxic effects at various sites essential to normal host cell function. Our approach to the development of antiviral agents consists of four points: ( 1 ) Understand the basic mechanisms of viral replication and elucidate differences between these and the normal essential cellular functions; (2) Understand the mechanisms by which the body naturally protects itself against viral infection; (3) Develop an agent which mimics the body’s natural defense mechanism; and (4) Show a correlation between the basic theoretical approach and activity at the tissue culture and whole animal levels of organization. Essentially, this involves selecting a model mechanism of action for an antiviral agent and then trying to find the specific agent. TABLE I lists the events that follow the infection of a cell by a ribonucleic acid (RNA) virus and the possible sites at which an antiviral agent might interfere with the multiplication of virus. For several reasons, we decided to study the replication of viral nucleic acid. We can see, in TABLE 2 the various enzyme systems that are involved in nucleic acid synthesis. For the moment, let us concentrate on RNA synthesis. Normal cellular RNA is synthesized from the four nucleoside triphosphates (NTP) by the enzyme RNA polymerase.2 The informational template for this synthesis is the normal cellular deoxyribonucleic acid (DNA), the genetic material. Baltimore and Franklin? have shown that the activity of this enzyme decreases after infection with an RNA virus. Many different groups3.4 have shown that after infection with an RNA virus there appears, within the cell, another RNA synthesizing enzyme which utilizes RNA as the informational template. We have found this enzyme, which we prefer to call RNA synthetase, in at least three different virusinfected cell systems: ( 1 ) Calf kidney cells infected with influenza B/Maryland; (2 ) Chick embryo fibroblasts infected with Newcastle’s Disease virus: and (3 ) Monkey kidney cells infected with rhinovirus. These enzymes require the presence of all four nucleoside triphosphates, are resistant lo deoxyribonuclease pretreatment, and are sensitive to ribonuclease pretreatment.” The product of the enzymatic reaction has been shown to be viral RNA; in our laboratories by means of biological tests and in Ochoa’s laboratory by means of physico-chemical criteria6 Thus, we have achieved our first goal, the characterization of an enzymatic reaction unique to, and essential for, RNA virus multiplication. Infection of an organism or tissue by a virus may be resisted in several ways: one of these is the production by the infected tissue of a substance that interferes with the multiplication of the virus. This substance, a protein of low molecular weight, is called interferon. It was discovered and purified by Isaacs’ group in London,’ and many other groups subsequently.8:’ Among its unusual properties is its species specificity.I0 That is, interferon derived from one virus-infected tissue is more effective in protecting the homologous rather than a heterologous tissue. Accordingly, there appear to be many interferons, the activity of each seeming to depend on the tissue from which it was derived, rather than on the particular virus that elicits its production.

VIRAL SYNTHETASE INHIBITORS AS ANTIVIRAL AGENTS

Nuciferine Ameliorates Inflammatory Responses by Inhibiting the TLR4-Mediated Pathway in Lipopolysaccharide-Induced Acute Lung Injury

Nisin Inhibition of Gram-Negative Bacteria

A novel sorbicillinoid compound as a potent anti-inflammation agent through inducing NLRP3 protein degradation

Atrial Natriuretic Peptide Attenuates Colitis Via Inhibition of the Cgas-Sting Pathway in Colonic Epithelial Cells

Anti‐inflammatory role demonstrated both in vitro and in vivo models using nonsteroidal tetranortriterpenoid, Nimbin (N1) and its analogs (N2 and N3) that alleviate the domestication of alternative medicine

Anti-Inflammatory Responses Produced with Nippostrongylus brasiliensis-Derived Uridine via the Mitochondrial ATP-Sensitive Potassium Channel and Its Anti-Atherosclerosis Effect in an Apolipoprotein E Gene Knockout Mouse Model

Abstract 12514: Elevated Intracellular Adenosine Epigenetically Regulates Endothelial Inflammation (best of Basic Science Abstract)

The anti-adhesion effect of nisin as a robust lantibiotic on the colorectal cancer cells

Naringin Exerts Therapeutic Effects on Mice Colitis: A Study Based on Transcriptomics Combined With Functional Experiments

Naringenin Prevents Oxidative Stress and Inflammation in LPS-Induced Liver Injury through the Regulation of LncRNA-mRNA in Male Mice

EFFECT OF PHOTODYNAMIC THERAPY ALONE OR COMBINED WITH POSTERIOR SUBTENON TRIAMCINOLONE ACETONIDE OR INTRAVITREAL BEVACIZUMAB ON CHOROIDAL HYPOFLUORESCENCE BY INDOCYANINE GREEN ANGIOGRAPHY

Antibacterial Peptide Nisin Activates p53 Gene Expression and Triggers Apoptosis in Human Colon Cancer Cells

Effect of nifedipine, a calcium channel blocker, on the generation of nitric oxide and interleukin-1β by murine macrophages activated by lipopolysaccharide from Prevotella intermedia

Immunomodulatory potential of Nisin A with application in wound healing

Niacin Modulates Pro-inflammatory Cytokine Secretion. A Potential Mechanism Involved in its Anti-atherosclerotic Effect

Columbianadin Suppresses Lipopolysaccharide (LPS)-Induced Inflammation and Apoptosis through the NOD1 Pathway

Nisin lantibiotic prevents NAFLD liver steatosis and mitochondrial oxidative stress following periodontal disease by abrogating oral, gut and liver dysbiosis

Naringin's Alleviation of the Inflammatory Response Caused by Actinobacillus pleuropneumoniae by Downregulating the NF-κB/NLRP3 Signalling Pathway

Nardosinanone N Suppresses LPS-induced Macrophage Activation by Modulating the Nrf2 Pathway and Mpges-1.

Euterpe oleracea Mart. Bioactive Molecules: Promising Agents to Modulate the NLRP3 Inflammasome